.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Teva
Chinese Patent Office
Farmers Insurance
Fish and Richardson
Cipla
Deloitte
Cerilliant
Fuji

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076019

« Back to Dashboard

NDA 076019 describes DEFEROXAMINE MESYLATE, which is a drug marketed by Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Watson Labs, and West-ward Pharms Int, and is included in five NDAs. It is available from three suppliers. Additional details are available on the DEFEROXAMINE MESYLATE profile page.

The generic ingredient in DEFEROXAMINE MESYLATE is deferoxamine mesylate. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.

Summary for 076019

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 076019

Mechanism of ActionIron Chelating Activity

Medical Subject Heading (MeSH) Categories for 076019

Suppliers and Packaging for NDA: 076019

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 076019 ANDA Hospira, Inc. 0409-2336 0409-2336-10 4 VIAL, SINGLE-USE in 1 CARTON (0409-2336-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE
DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 076019 ANDA Hospira, Inc. 0409-2336 0409-2336-13 10 VIAL, SINGLE-USE in 1 CARTON (0409-2336-13) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength500MG/VIAL
Approval Date:Mar 17, 2004TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/VIAL
Approval Date:Mar 17, 2004TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
Cipla
Fish and Richardson
Farmers Insurance
Merck
Chubb
Accenture
Healthtrust
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot